<?xml version="1.0" encoding="UTF-8"?>
<p>Baloxavir marboxil is another antiviral which was first developed in Japan and was shown to act as a selective cap-dependent endonuclease inhibitor of influenza viruses’ (both A and B) polymerase subunit PA. The drug had exhibited preferable safety, tolerability, and pharmacokinetic properties in a phase I trial [
 <xref rid="B113-vaccines-07-00053" ref-type="bibr">113</xref>]. The overall optimal performance against uncomplicated influenza among adults and adolescents, was shown during phase II and III trials that involved Japanese and Americans respectively [
 <xref rid="B114-vaccines-07-00053" ref-type="bibr">114</xref>]. The drug has currently been approved and marketed in the US as Xofluxa, for the treatment of acute uncomplicated influenza among ≥12 years [
 <xref rid="B115-vaccines-07-00053" ref-type="bibr">115</xref>].
</p>
